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We report three cases of recently named Bacteroides spp. isolates, two B. faecis 
isolates and one B. intestinalis isolate from clinical specimens of inpatients at a 
Korean tertiary-care hospital in 2011. All isolates were susceptible to piperacillin-
tazobactam, imipenem, meropenem, chloramphenicol, and metronidazole.
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Bacteroides fragilis group isolates are the most commonly encountered among the 
anaerobes in clinical specimens and are more virulent and resistant to antimicrobial 
agents than most other anaerobes.1 Among the B. fragilis group, B. fragilis was 
most common, followed by B. thetaiotaomicron, B. ovatus, and B. vulgatus.2,3 The 
taxonomy of Bacteroides has undergone significant changes in the past few years. 
Recently, several novel Bacteroides species were isolated from the microbiota of 
human feces. Bakir, et al.4-6 reported three novel species, B. finegoldii, B. dorei, and 
B. intestinalis from human feces in 2006. After that, additional cases of bacteremia 
caused by B. finegoldii and B. doreii were reported.7 Furthermore, B. nordii and B. 
salyersiae were first reported in 2004, and both isolates were recovered from hu-
man clinical specimens of intestinal origin such as peritoneal fluid, appendix tissue, 
and intra-abdominal abscess.8 B. faecis was isolated from human feces and was 
proposed to be a novel species in 2010.9 However, to our knowledge there have 
been no reported cases of infections caused by B. faecis or B. intestinalis. 
In this study, recently identified Bacteroides species, including two cases of B. 
faecis (case no. 1 and 2) and one case of B. intestinalis (case no. 3), were recov-
ered from clinical specimens of 3 inpatients at a Korean tertiary-care hospital in 
2011 (Table 1). A 55-year-old man (case no. 1) with a history of sigmoid colon 
cancer presented with a high fever of 38.4°C on the second day after surgery. On 
the third postoperative day, emergency reoperation was performed after anasto-
motic leakage was confirmed on an abdominal computed tomography (CT) scan. 
The patient recovered from peritonitis after treatment with piperacillin-tazobactam 
for 5 days. Additionally, a 70-year-old man (case no. 2) with a history of rectal 
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formed using the Clinical and Laboratory Standards Institute 
agar dilution method as previously described.10,11 Piperacillin 
and tazobactam (Yuhan, Seoul, Korea), cefoxitin (Merck 
Sharp & Dohme, West Point, PA, USA), cefotetan (Daiichi 
Pharmaceutical, Tokyo, Japan), clindamycin (Korea Upjohn, 
Seoul, Korea), imipenem and metronidazole (Choong Wae, 
Seoul, Korea), meropenem (Sumitomo, Tokyo, Japan), 
chloramphenicol (Chong Kun Dang, Seoul, Korea), and 
moxifloxacin (Bayer Korea, Seoul, Korea) were used.
Two isolates (case no. 1 and 2) were identified as B. fae-
cis by 16S rRNA gene sequencing; however, the Rapid ID 
32A system identified the isolates as B. ovatus/B. thetaio-
taomicron (Table 2). Additionally, MALDI-TOF MS sys-
tems identified B. thetaiotaomicron rather than B. faecis, as 
the latter species was absent from MALDI-TOF MS data-
bases. The B. intestinalis (case no. 3) isolate was misidenti-
fied as B. ovatus with Rapid ID 32A. The VITEK MS sys-
tem showed B. uniformis, but the MALDI Biotyper did not 
identify a specific strain. It is difficult to identify the novel 
Bacteroides spp. isolates by conventional methods using 
biochemical-reaction and MALDI-TOF MS systems, given 
that these strains were only recently described and few data 
have been accumulated on these species. Only 16S rRNA 
gene sequencing identified the newly discovered species.
Two B. faecis isolates were susceptible to piperacillin-
tazobactam, imipenem, meropenem, moxifloxacin, chlor-
amphenicol, and metronidazole, but non-susceptible to 
piperacillin, cefoxitin, cefotetan and clindamycin (Table 3). 
The antimicrobial susceptibility pattern of B. intestinalis (no. 
3) isolate was similar to that of the B. faecis isolates in this 
cancer presented with a fever of 38.1°C on the fifth postop-
erative day. Fluid collection in the pelvic cavity was ob-
served on a CT scan and an intra-abdominal infection was 
suspected. A course of piperacillin-tazobactam was admin-
istered for 9 days, and the fever subsided. Peritoneal fluid 
cultures of the above two patients were performed when 
they were febrile. 
The patient in case no. 3 was a 65-year-old woman with 
underlying hepatocellular carcinoma and thyroid cancer. 
She presented to the emergency department with abdomi-
nal pain as well as chills and fever. After admission, empiri-
cal treatment with teiocoplanin and imipenem was started 
for suspected biliary sepsis. Approximately 24 days after 
admission, an abdominal paracentesis was performed due 
to her increasing ascites volume. The patient underwent as-
cites fluid culture and cell count determinations. At that 
time, an antibiotic was infused once daily, and there was no 
evidence of high fever.
Peritoneal fluids were inoculated on blood culture medi-
um or conventional culture medium including 5% sheep 
blood agar, MacConkey agar, phenylethyl alcohol blood 
agar, and thioglycollate broth. Cultures grew 2‒4 bacteria 
strains including Bacteroides spp. (Table 1). All isolates were 
identified by Rapid ID 32A (bioMérieux, Marcy-l’Etoile, 
France) and the VITEK MS (bioMérieux) and matrix-assist-
ed laser desorption ionization (MALDI) Biotyper (Bruker 
Daltonics, Bremen, Germany) MALDI-time of flight mass 
spectrometry (MALDI-TOF MS) systems. For further identi-
fication of the bacterial species, 16S rRNA gene sequencing 
was performed. Antimicrobial susceptibility testing was per-
Table 1. Clinical Characteristics and Bacterial Culture Results
Case Sex/age Underlying disease Operation history
Peritoneal fluid culture by
Conventional method Blood culture bottles
1 M/55 Sigmoid colon cancer Yes Bacteroides faecis, Enterococcus faecalis,   Pseudomonas aeruginosa, P. mendocina Not tested
2 M/70 Rectal cancer Yes No growth B. faecis,   Staphylococcus hominis
3 F/65 Hepatocellular   carcinoma No
Bacteroides intestinalis, Clostridium 
  clostridiiforme, E. faecalis, Citrobacter freundii
B. intestinalis, E. faecalis, 
  C. freundii
Table 2. Species Identification Using the Four Methods
Case 16S rRNA gene sequencing Rapid ID 32A
MALDI-TOF MS systems
VITEK MS MALDI biotyper
1 B. faecis* B. ovatus/B. thethaiotaomicron B. thethaiotaomicron B. thethaiotaomicron
2 B. faecis B. ovatus/B. thethaiotaomicron B. thethaiotaomicron B. thethaiotaomicron
3 B. intestinalis B. ovatus B. uniformis ND
ND, not detected; MALDI, matrix-assisted laser desorption ionization; TOF MS, time of flight mass spectrometry.
*Species absent from two MALDI-TOF MS databases.
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study, except that B. intestinalis isolate showed nonsuscepti-
bility to moxifloxacin. Antimicrobial susceptibility patterns 
of Bacteroides spp. isolates in this study were similar to 
those of B. fragilis group isolates, as shown in previous re-
ports from Korea.11 
This is the first report of B. faecis and B. intestinalis 
strains isolated in clinical specimens. We were unable to 
demonstrate the clinical significance of B. faecis and B. in-
testinalis isolates in our patients due to their postoperative 
status and polymicrobial infections. However, the isolation 
of anaerobic bacteria from clinical specimens is a necessary 
cause for concern, as anaerobes detected in polymicrobial 
infections can occasionally spread to the bloodstream and 
have serious consequences.
In conclusion, the recently named B. faecis and B. intesti-
nalis isolates were recovered from clinical specimens; thus, 
it is necessary during the assessment of infections to con-
sider these new Bacteroides spp. isolates as possible causes.
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Table 3. Antimicrobial Susceptibility Patterns and MIC Values (µg/mL) of Bacteroides spp. Isolates
Case isolates 1B. faecis
2
B. faecis
3
B. intestinalis
Piperacillin 64 I 64 I 128 R
PIP-TZ 16 S 16 S 1 S
Cefoxitn 64 R 64 R 64 R
Cefotetan 256 R 256 R 256 R
Imipenem 0.25 S   0.25 S 0.5 S
Meropenem 0.25 S   0.25 S 1 S
Clindamycin 2 S 4 I 2 S
Moxifloxacin 2 S 1 S 4 I
Chloramphenicol 8 S 8 S 4 S
Metronidazole 2 S 2 S 2 S
Tigecycline 1 NA 0.5 NA 1 NA
PIP-TZ, piperacillin-tazobactam; S, susceptible; I, intermediate; R, resistant; NA, not applicable.
